Type 2 diabetes and hypoglycemia

Researchers find diminished cardiovascular gains and an increased risk for severe hypoglycemia in frail people with type 2 diabetes given intensive glycemic and blood pressure treatment.

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.

A novel weekly insulin achieves similar glycemic control to insulin degludec at a higher fasting glucose target, report the investigators at the virtual ENDO 2021 meeting.

Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

The results of the phase 2 LIBERATES trial suggest that flash glucose monitoring could reduce the time people with type 2 diabetes spend in hypoglycemia in the period following an acute coronary syndrome.

Severe hypoglycemia in people with type 2 diabetes is associated with later mortality from a wide range of causes, including those for which there is no obvious underlying mechanism, say researchers.

A large population-based study supports an increased risk for diabetic ketoacidosis for users of SGLT2 inhibitors compared with DPP-4 inhibitors, although the absolute risk remains low.

People with type 2 diabetes who use ultra-rapid insulin lispro as part of a basal–bolus regimen achieve similar overall glycemic control and better control of postprandial glucose excursions compared with those using standard lispro, report the PRONTO-T2D investigators.

Predictive low glucose alerts are associated with a reduced frequency and severity of rebound hyperglycemia among people using real-time continuous glucose monitoring, show study findings presented at the virtual ADA 80th Scientific Sessions.

Real-world data presented at the virtual ADA 80th Scientific Sessions highlight the benefits of the FreeStyle Libre continuous glucose monitoring system in reducing acute complications in people with type 1 or type 2 diabetes.

Chinese researchers say that some COVID-19 patients present with ketosis, which may progress to diabetic ketoacidosis in those with diabetes.

Hospitalized people with poorly controlled type 2 diabetes who are treated with insulin glargine U300 have comparable glycemic control to those given the U100 formulation, and may have a lower risk for hypoglycemia, researchers report.

A large observational study reveals a strong link between reduced kidney function and increased incidence of hypoglycemia in adults with diabetes in routine clinical practice.

A post-hoc analysis of the DECLARE-TIMI 58 trial suggests that the sodium-glucose cotransporter-2 inhibitor dapagliflozin has a favorable safety profile in a broad population of patients with type 2 diabetes.

A clinical decision-making tool to assist type 2 diabetes management during fasting for Ramadan results in significant reductions in glycated hemoglobin and improvements in fasting blood glucose, researchers report.

A large study backs hyperosmolarity as a key risk stratification factor for patients admitted to hospital with diabetic ketoacidosis.

Fasting C-peptide levels can “provide valuable information” to guide the approach to titrating basal insulin in new users with type 2 diabetes, say researchers.

Real-world, off-label sodium–glucose cotransporter 2 inhibitor use is uncommon in people with type 1 diabetes but appears to be associated with a higher than expected rate of diabetic ketoacidosis when compared with clinical trials, US researchers report.

Almost one in 10 people with type 2 diabetes who begin basal insulin therapy through the Medicare health program experience hypoglycemia within 6 months, US research suggests.

Glycated hemoglobin levels correlate strongly with continuous glucose monitoring-measured average blood glucose and hyperglycemia, but poorly with hypoglycemia, say researchers.